Fig. 1 · Structure

Documents & Downloads

Mercaptopurine

Cat. No. A10568 CAS 50-44-2
Mercaptopurine has been shown to interfere with DNA and RNA synthesis and cause inhibition of de novo purine syntehsis.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
PRPP Amidotransferase

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 47 μM Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay [PMID: 28923386]
A549 IC50 47 μM Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay [PMID: 22705001]
A549 IC50 47 μM Cytotoxicity against human A549 cells at lag phase of growth after 48 hrs by MTT assay [PMID: 19711987]
A549 IC50 49.3 μM Cytotoxicity against human A549 cells at exponential phase of growth after 48 hrs by MTT assay [PMID: 19711987]
A549 IC50 49.4 μM Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay [PMID: 28923386]
ASPC1 IC50 2.45 μM Cytotoxicity against human Aspc-1 cells by crystal violet staining [PMID: 20930123]
B16 IC50 0.8 μg/mL Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay [PMID: 7807120]
C6 IC50 30.2 μg/mL Cytotoxicity against rat C6 cells assessed as cell viability after 96 hrs by MTT assay [PMID: 11087619]
CCRF-CEM CC50 1 μM Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay [PMID: 21741130]
CCRF-CEM IC50 1 μM Antiproliferative activity against human CCRF-CEM cells by MTT assay [PMID: 17254669]
CCRF-SB IC50 1 μM Antiproliferative activity against human CCRF-SB cells by MTT assay [PMID: 17254669]
CCRF-SB CC50 1.1 μM Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay [PMID: 21741130]
COLO357 IC50 6.12 μM Cytotoxicity against human Colo-357 cells by crystal violet staining [PMID: 20930123]
CRL-7065 cell line IC50 > 100 μM Antiproliferative activity against human CRL7065 cells by MTT assay [PMID: 17254669]
DAN-G IC50 4.06 μM Cytotoxicity against human DAN-G cells by crystal violet staining [PMID: 20930123]
Daudi IC50 > 200 μM Antiproliferative activity against human Daudi cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay [PMID: 18467007]
DU-145 CC50 2 μM Antiproliferative activity against human DU145 cells after 96 hrs by MTT assay [PMID: 21741130]
DU-145 IC50 2 μM Antiproliferative activity against human DU145 cells by MTT assay [PMID: 17254669]
HEK293 IC50 0.007 μM Antiproliferative activity against HEK293 cells assessed as reduction of cell growth after 72 hrs by MTT method [PMID: 10757708]
HEK293 IC50 0.007 μM Antiproliferative activity against HEK293 cells after 3 days by MTT conversion assay [PMID: 16643040]

20 records · Scroll to view more

Mercaptopurine Research Summary

This section summarizes 2 in vitro studies of Mercaptopurine from 2 published references. In vitro models include hTERT-BJ1 fibroblasts; WT MEFs.

Mercaptopurine In Vitro Studies

Mercaptopurine treatment increased production of L-lactate or β-hydroxybutyrate (β-HB) in hTERT-BJ1 fibroblasts compared with vehicle. In WT MEFs, Mercaptopurine added to the medium did not trigger ISG expression. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Mercaptopurine increases metabolite production in fibroblasts

Cell-based study · hTERT-BJ1 fibroblasts [1]

In hTERT-BJ1 fibroblasts, Mercaptopurine treatment increased production of L-lactate or β-hydroxybutyrate (β-HB) compared with vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
L-lactate and β-hydroxybutyrate (β-HB) concentrationReported result an increase in their production of L-lactate or β-HB compared to vehicle[1]

Literature-Reported Treatment Conditions

Exposure duration
48 or 72 h
Method
drug treatments were added
Reported limits
Not stated in the sentences used: dose, vehicle.
Methods and source locations

Compound reported in the paper: Mercaptopurine; Compound label in the paper: 6-Mercaptopurine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS (S3); MATERIALS AND METHODS > L-lactate assay, β-hydroxybutyrate assay, glucose consumption (S85, S91)

L-lactate and β-hydroxybutyrate (β-HB) concentration: L-lactate and β-hydroxybutyrate (β-HB) concentration; comparator: vehicle — RESULTS (S3)

Mercaptopurine does not trigger ISG expression in WT MEFs

Cell-based study · WT MEFs (n = 1) [2]

In WT MEFs, Mercaptopurine added to the medium did not trigger ISG expression.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ISG expressionReported result 6-mercaptopurine did not trigger ISG expression[2]

Literature-Reported Treatment Conditions

Exposure duration
16 h
Method
added to the medium
Reported limits
Not stated in the sentences used: dose, vehicle, control.
Methods and source locations

Compound reported in the paper: Mercaptopurine; Compound label in the paper: 6-Mercaptopurine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Impaired pyrimidine synthesis drives mtDNA immune signalling (S127); Methods > Cell culture, transfection and RNA interference (S216); Fig. 7 legend (S348)

ISG expression: ISG expression — Results > Impaired pyrimidine synthesis drives mtDNA immune signalling (S127); Fig. 7 legend (S348)

Specifications

Manufacturer Adooq Bioscience
CAS Number 50-44-2
Formula C5H4N4S
Molecular Weight 152.18
Synonyms 6-Mercaptopurine
SMILES
C1=NC2=C(N1)C(=S)N=CN2

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 28 mg/mL (183.99 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Mercaptopurine Research References

  1. [1] Peiris-Pagès M, Sotgia F, Lisanti MP. Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine Hedgehog-GLI signalling in breast cancer cells. Oncotarget (2015). PMID: 25915429 DOI: 10.18632/oncotarget.3828 Source material
  2. [2] Sprenger HG, MacVicar T, Bahat A, et al. Cellular pyrimidine imbalance triggers mitochondrial DNA-dependent innate immunity. Nat Metab (2021). PMID: 33903774 DOI: 10.1038/s42255-021-00385-9 Source material

Added to your cart

View Cart Checkout
Loading...